Emerging-Market Specialist Nycomed Acquires Majority Stake In China's Guangdong Techpool Bio-Pharma
This article was originally published in The Pink Sheet Daily
Executive Summary
Swiss Nycomed has acquired a majority stake in Guangdong Techpool Bio-Pharma for €210 million to expand its Chinese operations.
You may also be interested in...
Nycomed To Beef Up Sales In China Through Buyout; Bets On India For Global API Supplies
MUMBAI - Having established itself firmly among the top 10 pharma companies in Russia, Zurich-headquartered Nycomed now plans to dig deeper into the fast-growing Chinese market through the acquisition of a sales and distribution team
Pipeline Acquisitions, Co-Promotion Deals, To Drive Ipsen
Ipsen’s business strategy calls for accessing external innovation across its pipeline, combined with geographic expansion, realizing the unmet potential of its marketed products and business efficiencies in manufacturing and operations.
Denmark's IO Vaccine Biotech Attracts Investor Interest
Copenhagen-based start-up IO Biotech has raised a hefty €127m from a group of VC investors to accelerate its IDO- and PD-L1 targeted immuno-oncology approaches to the treatment of cancer.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: